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POLYPEPTIDES, SYSTEMS, AND METHODS

ous manner, at ambient temperatures, With operability for

clinical use, reliability, speci?city, and sensitivity.

USEFUL FOR DETECTING GLUCOSE
RELATED APPLICATIONS

SUMMARY

This application claims priority from US. Provisional
Application Ser. Nos. 60/954,269 ?led on Aug. 6, 2007, and
60/954,348 ?led on Aug. 7, 2007, the entire disclosures of
Which are incorporated herein by this reference.

The presently-disclosed subject matter meets some or all of
the above-identi?ed needs, as Will become evident to those of

ordinary skill in the art after a study of information provided
in this document.
This Summary describes several embodiments of the pres
ently-disclosed subject matter, and in many cases lists varia

TECHNICAL FIELD

tions and permutations of these embodiments. This Summary
is merely exemplary of the numerous and varied embodi

The presently-disclosed subject matter relates to biosen
sors, and systems and methods useful for detecting glucose.

ments. Mention of one or more representative features of a

BACKGROUND

ment can typically exist With or Without the feature(s) men

given embodiment is likeWise exemplary. Such an embodi
tioned; likeWise, those features can be applied to other
Monitoring blood glucose levels in a diabetic individual is
important for maintaining metabolic control in the individual.

Currently-available systems and methods of monitoring glu

embodiments of the presently-disclosed subject matter,
20

Whether listed in this Summary or not. To avoid excessive

repetition, this Summary does not list or suggest all possible

cose levels require extraction of blood from the diabetic indi

combinations of such features.

vidual at multiple times during each day, e.g., ?nger prick. As
such, only information about blood glucose levels at discrete
time points is made available. Additionally, extracting blood

embodiments, a biosensor for detecting a molecule of inter
est. In some embodiments, the biosensor comprises an iso

The presently-disclosed subject matter provides, in some
25

for use in testing can be painful, and as a result, can lead to loW

lated polypeptide molecule capable of selectively-binding

compliance or non-compliance by diabetic individuals.

glucose. In some embodiments, the polypeptide molecule is
selected from: an unnatural analogue of Wild type glucose

Efforts have therefore been made to develop an effective

binding protein; a fragment of Wild type glucose binding

system and method for monitoring blood glucose levels in a
continuous and less invasive manner. Biosensors have been

30

proposed for use in the in vivo, continuous detection of blood
analyte levels. A biosensor includes an element capable of
speci?cally detecting an analyte of interest, alloWing a mea
surable signal to be produced, Which can be correlated to

analyte concentration.

35

Biosensors for detecting glucose can include an element

amino acids are truncated from the N-terminus and/or
Wherein up to about 83 amino acids are truncated from the

C-terminus of SEQ ID NO: 1. In some embodiments, the
polypeptide molecule is a fragment of the amino acid
sequence of SEQ ID NO: 5, Wherein up to about 12 amino
45

acids are truncated from the N-terminus and/or Wherein about

99 amino acids are truncated from the C-terminus of SEQ ID

absence of glucose) the tWo domains are far apart and the cleft

is exposed to the solvent, While in the closed form the glucose
is engulfed in the cleft.
Although biosensors have made use of certain WtGBPs,

label to generate a signal, such that the glucose can be
detected.
In some embodiments, the polypeptide molecule is a frag

ment of Wild type glucose binding protein. In some embodi
ments, the polypeptide molecule is a fragment of the amino
acid sequence of SEQ ID NO: 1, Wherein up to about 13

that selectively binds glucose. For example, Wild type glucose
binding protein (WtGBP) is capable of binding glucose. GBP
of Escherichia coli is a 33 kDa periplasmic binding protein.
GBP consists of tWo distinctly similarly folded globular
domains that are connected to each other by three peptide
segments. The sugar binding site is located in the cleft of the
protein formed betWeen the tWo domains. The binding of
glucose is accompanied by a conformational change of the
protein at the hinge region. In the open form of GBP (in the

protein; and an unnatural analogue fragment of Wild type
glucose binding protein. The biosensor further comprises a
label associated With the polypeptide molecule, Wherein
binding of glucose to the polypeptide molecule causes the

NO: 5. In some embodiments, the polypeptide molecule,
comprises the amino acid sequence of SEQ ID NOs: 1-7.
In some embodiments, the polypeptide molecule is an
50

unnatural analogue of Wild type glucose binding protein,

such biosensors have drawbacks. For example, GBPs are not
very stable at room temperature. As such, there are apparent
problems associated biosensors that make use of WtGBP for

Wherein one or more natural amino acids of Wild type glucose
binding protein are replaced With one or more unnatural

monitoring blood glucose levels in diabetic patients. Further

amino acids of Wild type glucose binding protein are replaced

amino acids. In some embodiments, the one or more natural

more, currently-available systems and methods for continu
ously-detecting glucose are associated With a signi?cant
inability to detect glucose levels in the hypoglycemic ranges

55 With one or more unnatural amino acids as set forth in Table

in a reliable manner. Further, these available systems also
suffer from short lifespans and are not easily used for routine

Wherein one or more natural leucines are replaced With
unnatural leucines. In some embodiments, one or more natu

clinical use. In addition, the use of current WtGBPs for con

A. In some embodiments, the polypeptide molecule is an

unnatural analogue or an unnatural analogue fragment,

60

ral leucines are replaced With 5,5,5-tri?uoroleucine. In some

tinuous blood glucose monitoring for implantable or catheter
based devices is complicated by the need for sterilization. The
development of novel proteins With improved thermal and

more natural tryptophans are replaced With 5-?uorotryp

chemical stability Will lead to easier and more cost-effective

tophan. In some embodiments, one or more natural tryp

means of sterilization.

Accordingly, there is a need in the art for systems and
methods for detecting glucose levels in a subject in a continu

embodiments, one or more natural leucines are replaced With
5,5,5-tri?uoro-DL-leucine. In some embodiments, one or

65

tophans are replaced With 5-?uoro-L-tryptophan.
In some embodiments, the polypeptide molecule is stable
over a Wider range of temperatures relative to WtGBP. In some

US 8,465,981 B2
3

4

embodiments, the polypeptide molecule is stable at tempera

the structure of the truncated form speci?ed by the ?gure and
the light gray portion represents the portion of the WtGBP that
is being omitted.

tures betWeen about 55° C. and about 75° C.
In some embodiments, the label is a ?uorophore. In some

embodiments, label is the ?uorophore MDCC. In some

FIG. 2C is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 7. The structure shoWn is a
truncated form of the complete WtGBP from T maritime

embodiments, binding of glucose to the polypeptide mol
ecule causes the label to generate a detectably altered ?uo

rescence intensity of the ?uorophore such that the glucose can
be detected. In some embodiments, the ?uorescence intensity

shoWn in FIG. 2A, in Which the dark gray portion represents
the structure of the truncated form speci?ed by the ?gure and
the light gray portion represents the portion of the WtGBP that
is being omitted.

can be correlated to the concentration of the glucose in a

sample.
In some embodiments, the label is attached to an amino

FIG. 3 is a dose response curve for glucose With an unnatu

acid site of the polypeptide molecule selected from Asp 13,

ral analogue of a WtGBP, including the isolated polypeptide
of SEQ ID NO: 1, Where natural tryptophans are replaced
With 5 -?uorotryptophans;

Asp 44, Val 68, Ala 71, Phe 90, Lys 92, Glu 93, Pro 94, Lys
97,Gly 109, Thr 110,Asp 111,Gly 151, Pro 153,Ala 155,Asp
184, Asp 212, Leu 255, Ala 258,Asn 260, Ala 262, Arg 292,
Val 293, and Pro 294.
In some embodiments of the presently-disclosed subject
matter, a method for detecting a glucose molecule is pro
vided. In some embodiments, the method comprises contact
ing a biosensor disclosed herein With a sample of interest;

FIG. 4 is a dose response curve for glucose With an unnatu

ral analogue fragment of a WtGBP, including the isolated
polypeptide of SEQ ID NO: 2, Where natural tryptophans are

replaced With 5-?uorotryptophans;
20

FIG. 5 is a dose response curve for glucose With an unnatu

ral analogue fragment of a WtGBP, including the isolated
polypeptide of SEQ ID NO: 3, Where natural tryptophans are

detecting the signal; and collecting and displaying the signal
With a detection and data collection device, to thereby detect
the glucose. In some embodiments, the glucose is continu

replaced With 5-?uorotryptophans;

ously detected.

FIG. 6 is a dose response curve for glucose With an unnatu
25

BRIEF DESCRIPTION OF THE FIGURES

ral analogue of a WtGBP, including the isolated polypeptide
of SEQ ID NO: 1, Where natural leucines are replaced With

5,5,5-tri?uoroleucines;
FIG. 1A is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 1. The 3D structures Were

created using a protein structure modeling program called DS
VieWer Pro. Structural information for proteins is available
online through the RCSB Protein Data Bank. This structural

FIG. 7 is a dose response curve for glucose With an unnatu
30

replaced With 5,5,5-tri?uoroleucines;
FIG. 8 is a dose response curve for glucose With an unnatu

information is available in the form of a ?le that contains the

ral analogue fragment of a WtGBP, including the isolated
polypeptide of SEQ ID NO: 3, Where natural leucines are

coordinates in three dimensions for proteins such as they have
been published in current literature sources. Protein structure

35

?les are available by PDB#. In this document, the PDB ?les
used are as folloWs: #1GLG(WtGBP fromE. cali) and #2H3H

FIG. 9 is a dose response curve for glucose With an unnatu

(WtGBP from T marilima), FIG. 1A and FIG. 2A, respec

ture of the truncated form speci?ed by the ?gure and the light
gray portion represents the portion of the WtGBP that is being
omitted.
FIG. 1C is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 3. The structure shoWn is a
truncated form of the complete WtGBP from E. coli shoWn in
FIG. 1A, in Which the dark gray portion represents the struc

immobiliZed on a ?ber optic tip;
FIG. 10 is a circular dichroism (CD) spectrum of an
40

FIG. 11 is a CD spectrum of a WtGBP, including the iso

lated polypeptide of SEQ ID NO: 1.
45

shoWn in FIG. 2A, in Which the dark gray portion represents

FIG. 12 are tWo graphs shoWing a comparison of the ?uo
rescence emission intensity of GBP and GRP-7-AZatryp

tophan.
FIG. 13 is a CD spectrum shoWing a comparison of the
?uorescence emission intensity over a range of temperatures
50

of GRP-7-AZatryptophan Without (light grey line) or With

(dark grey line, shifted right toWard higher temperature)
bound glucose.
BRIEF DESCRIPTION OF THE SEQUENCE
55

LISTING

SEQ ID NO: 1 includes an amino acid sequence for Wild

type glucose binding protein (WtGBP) from Escherichia coli

ture of the truncated form speci?ed by the ?gure and the light
gray portion represents the portion of the WtGBP that is being
omitted.
FIG. 2A is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 5. The 3D structures Were
created using DS VieWer Pro.
FIG. 2B is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 6. The structure shoWn is a
truncated form of the complete WtGBP from T maritime

unnatural analogue of a WtGBP, including the isolated
polypeptide of SEQ ID NO: 2, Where natural leucines are

replaced With 5,5,5-tri?uoroleucines; and

ture of the truncated form speci?ed by the ?gure and the light
gray portion represents the portion of the WtGBP that is being
omitted.
FIG. 1D is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 4. The structure shoWn is a
truncated form of the complete WtGBP from E. coli shoWn in
FIG. 1A, in Which the dark gray portion represents the struc

replaced With 5,5,5-tri?uoroleucines;
ral analogue of WtGBP including unnatural tryptophan,

tively.
FIG. 1B is a rendering of the three-dimensional structure of
the polypeptide of SEQ ID NO: 2. The structure shoWn is a
truncated form of the complete WtGBP from E. coli shoWn in
FIG. 1A, in Which the dark gray portion represents the struc

ral analogue fragment of a WtGBP, including the isolated
polypeptide of SEQ ID NO: 2, Where natural leucines are

60

65

(GenBank Accession number X05646). The disclosed
sequence provided is Without the N-terminal signaling pep
tide.
SEQ ID NO: 2 includes an amino acid sequence for tGBPl,
including amino acids 14-296 of SEQ ID NO: 1.
SEQ ID NO: 3 includes an amino acid sequence for tGBP2,
including amino acids 14-256 of SEQ ID NO: 1.
SEQ ID NO: 4 includes an amino acid sequence for tGBP3,
including amino acids 14-226 of SEQ ID NO: 1.

US 8,465,981 B2
6

5

closed subject matter further includes biosensors, systems,
and methods for detecting glucose.
The presently-disclosed subject matter includes isolated
polypeptide molecules that are capable of selectively-binding
glucose, and biosensors that include isolated polypeptide
molecules that are capable of selectively-binding glucose. In

SEQ ID NO: 5 includes an amino acid sequence for Wild

type glucose binding protein (WtGBP) from Thermologa
marilima (GenBank® Accession No. NPi227930), Where
the ?rst 31 amino acids making up the N-terminal signaling
peptide have been removed.
SEQ ID NO: 6 includes an amino acid sequence for tGRP4,
including amino acids 13-253 of SEQ ID NO: 5.
SEQ ID NO: 7 includes an amino acid sequence for tGRP5,
including amino acids 13-205 of SEQ ID NO: 5.

some embodiments, the isolated polypeptide molecule is a

fragment of a Wild type glucose binding protein (WtGBP). In
some embodiments, the isolated polypeptide molecule is an
unnatural analogue of WtGBP. In some embodiments, the

isolated polypeptide molecule is an unnatural analogue frag

DESCRIPTION OF EXEMPLARY
EMBODIMENTS

ment of WtGBP.

The terms “polypeptide,

The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document. Modi
?cations to embodiments described in this document, and

other embodiments, Will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and

protein amino acids, including modi?ed amino acids (e.g.,
phosphorylated, glycated, etc.) and amino acid analogs,
regardless of siZe or function. Although “protein” is often
used in reference to relatively large polypeptides, and “pep
20

particularly the speci?c details of the described exemplary
embodiments, is provided primarily for cleamess of under
standing and no unnecessary limitations are to be understood

therefrom.

Some of the polynucleotide and polypeptide sequences

protein,” and “peptide,” Which

are used interchangeably herein, refer to a polymer of the 20

25

tide” is oftenused in reference to small polypeptides, usage of
these terms in the art overlaps and varies. The term “peptide”
as used herein refers to peptides, polypeptides, proteins, and
fragments of proteins, unless otherWise noted. The terms

“protein”, “polypeptide”, and “peptide” are used inter
changeably herein When referring to a gene product and frag
ments thereof. Thus, exemplary polypeptides include gene

disclosed herein are cross-referenced to GENBANK® acces

products, naturally occurring proteins, homologs, orthologs,

sion numbers. The sequences cross-referenced in the GEN
BANK® database are expressly incorporated by reference as
are equivalent and related sequences present in GENBANK®

paralogs, fragments, and other equivalents, variants, frag

or other public databases. Also expressly incorporated herein

ments, and analogs of the foregoing. In some embodiments,
the term polypeptide includes a conservatively substituted
30

by reference are all annotations present in the GENBANK®
database associated With the sequences disclosed herein.
While the folloWing terms are believed to be Well under
stood by one of ordinary skill in the art, the folloWing de?ni
tions are set forth to facilitate explanation of the presently
disclosed subject matter.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to Which the presently

35

disclosed subject matter belongs. Although any methods,

40

peptide comprising an amino acid residue sequence that dif
fers from a reference peptide by one or more conservative
amino acid substitution, and maintains some or all of the

activity of the reference peptide as described herein. A “con
servative amino acid substitution” is a substitution of an

devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presently

amino acid residue With a functionally similar residue.
Examples of conservative substitutions include the substitu
tion of one non-polar (hydrophobic) residue such as isoleu
cine, valine, leucine or methionine for another; the substitu
tion of one polar (hydrophilic) residue for another such as

betWeen arginine and lysine, betWeen glutamine and aspar
agine, betWeen glycine and serine; the substitution of one

disclosed subject matter, representative methods, devices,

basic residue such as lysine, arginine or histidine for another;

and materials are noW described.

Following long-standing patent laW convention, the terms

variant.
The term “conservatively substituted variant” refers to a

application, including the claims. Thus, for example, refer

or the substitution of one acidic residue, such as aspartic acid
or glutamic acid for another.
The term “isolated,” When used in the context of an isolated

ence to “a cell” includes a plurality of such cells, and so forth.

polypeptide, is a polypeptide that, by the hand of man, exists

45

“a”, “an”, and “the” refer to “one or more” When used in this

Unless otherWise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,

apart from its native environment and is therefore not a prod
50

and so forth used in the speci?cation and claims are to be

uct of nature.

properties sought to be obtained by the presently-disclosed

As used herein, the term “selectively-bind” refers to an
interaction betWeen glucose and a binding site of a polypep
tide molecule. In some embodiments, the interaction betWeen
glucose and the binding site can be identi?ed as “selective” if:
the equilibrium dissociation constant (K) is about the same
or less than the Kd of glucose and a reference polypeptide

subject matter.

binding site; the equilibrium inhibitor dissociation constant

As used herein, the term “about,” When referring to a value
or to an amount of mass, Weight, time, volume, concentration

(K1) is about the same or less than the K- of glucose and a
reference polypeptide binding site; or the effective concen

or percentage is meant to encompass variations of in some 60

tration at Whichbinding of glucose is inhibited by 50% (ECSO)

understood as being modi?ed in all instances by the term
“about”. Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this speci?cation and claims
are approximations that can vary depending upon the desired

55

is about the same or less than the EC5O of glucose and a

embodiments 120%, in some embodiments 110%, in some
embodiments 15%, in some embodiments 11%, in some
embodiments 10.5%, and in some embodiments 10.1% from
the speci?ed amount, as such variations are appropriate to

perform the disclosed method.
The presently-disclosed subject matter includes isolated

polypeptides useful for detecting glucose. The presently-dis

reference polypeptide binding site. For example, glucose
selectively binds an isolated polypeptide molecule that is a

fragment, unnatural analogue, or unnatural analogue frag
65

ment of Wild type Glucose Binding Protein (WtGBP) if the
Kd, Ki, and/or EC5O is about the same or less than the Kd of
glucose and WtGBP.

US 8,465,981 B2
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polypeptide molecule comprises a fragment of WtGBP from
T marilima including amino acids 13-253, set forth in SEQ
ID NO: 6 (referred to herein as tGBP4). For another example,
in some embodiments, the polypeptide molecule comprises a
fragment of WtGBP from T marilima including amino acids

In some embodiments, the interaction between glucose and
the binding site can be identi?ed as “selective” When the

equilibrium dissociation constant (Kd) is less than about 100
nM, 75 nM, 50 nM, 25 nM, 20 nM, 10 nM, 5 nM, or 2 nM. In
some embodiments, the interaction betWeen glucose and the
binding site can be identi?ed as “selective” When the equilib
rium inhibitor dissociation constant (K) is less than about is

13-205, set forth in SEQ ID NO: 7 (referred to herein as

tGBP5).

less than about 100 11M, 75 11M, 50 11M, 25 11M, 20 11M, 10 11M,

It is contemplated that isolated polypeptide molecules of
the presently-disclosed subject matter can be fragments and/

5 11M, or 2 11M, When competing With glucose. In some
embodiments, the interaction betWeen glucose and the bind

or unnatural analogues of WtGBP for various species, or an

ing site can be identi?ed as “selective” When the effective

isolated polypeptide molecule having a three-dimensional

concentration at Which glucose binding is inhibited by 50%
(ECSO) is less than about 500 11M, 400 11M, 300 11M, 100 11M,
50 11M, 25 11M, or 10 11M.
The terms “polypeptide fragment” or “fragment”, When

structure that is suf?ciently similar to such a WtGBP or func

tional fragment thereof, such that it is capable of speci?cally
binding glucose. Three-dimensional structures of the isolated

used in reference to a polypeptide, refers to a polypeptide in
Which amino acid residues are absent as compared to the

polypeptide molecules of SEQ ID NOS: 1-7 are provided in

full-length reference polypeptide itself, but Where the remain

tein structure modeling program called DS Viewer Pro. Struc

FIGS. 1A-2C. These 3D structures Were created using a pro

tural information for proteins is available online through the

ing amino acid sequence is usually identical to the corre
tions can occur at the amino-terminus or carboxy-terminus of

RCSB Protein Data Bank. This structural information is
available in the form of a ?le that contains the coordinates in

the reference polypeptide, or alternatively both. A fragment

three dimensions for proteins such as they have been pub

can retain one or more of the biological activities of the

lished in current literature sources. Protein structure ?les are

sponding positions in the reference polypeptide. Such dele

reference polypeptide. In some embodiments, a fragment can
comprise a domain or feature, and optionally additional

20

available by PDB#. In the present context, the PDB ?les used

As used herein, the term “unnatural analogue” refers to a

are as folloWs: #IGLG (WtGBP from E. coli) and #2H3H
(WtGBP from T marilima). These structures are shoWn in
FIG. 1A and FIG. 2A respectively. Structures shoWn in FIG.
1B, FIG. 1C, and FIG. ID are truncated forms of the complete
WtGBP from E. coli shoWn in FIG. 1A in Which the dark gray

polypeptide Wherein one or more natural amino acids are 30

portion represents the structure of the truncated form speci

replaced With unnatural amino acids, relative to a reference
polypeptide. Examples of unnatural amino acids are set forth

?ed by that ?gure and the light gray portion represents the
portion of the WtGBP that is being omitted. Likewise, FIG. 2B

in Table A, provided herein beloW.
As used herein, the term “unnatural analogue fragment”

WtGBP from T maritime shoWn in FIG. 2A in Which the dark

25

amino acids on one or both sides of the domain or feature,

Which additional amino acids can number from 5, 10, 15, 20,
or more residues.

and FIG. 2C represent truncated forms of the complete

refers to a polypeptide fragment Wherein one or more natural 35 gray portion represents the structure of the truncated form

amino acids are replaced With unnatural amino acids, relative

speci?ed by that ?gure and the light gray portion represents

to a reference polypeptide.
As used herein, WtGBP refers to a reference protein includ

the portion of the WtGBP that is being omitted.
In some embodiments, the polypeptide molecule of the
presently-disclosed subject matter comprises a fragment of

ing the amino acid residues of a full-length Wild type glucose

binding protein. A full-length Wild type glucose binding pro

40

WtGBP, Whereinup to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,

tein Will be knoWn to those of ordinary skill in the art. Some

15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids are

embodiments of the polypeptide molecule of the presently

truncated from the N-terminus of the WtGBP. In some

disclosed subject matter can be described With reference to
the amino acid residues of a WtGBP. In some embodiments,
the WtGBP can be a full-length WtGBP from E. coli (Gen

embodiments, the polypeptide molecule comprises a frag
ment ofWtGBP, Wherein up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
45

Bank® Accession No. X05646). In some embodiments, the
WtGBP can be the polypeptide of SEQ ID NO: 1. In some
embodiments, the WtGBP can be a full-length WtGBP from T
marilima (GenBank® Accession No. NPi227930). In some
embodiments, the WtGBP can be the polypeptide of SEQ ID

50

109, or 1 10 amino acids are truncated from the C-terminus of
WtGBP.

NO: 5. In some embodiments, the WtGBP can be a full-length

WtGBP from Thermus lhermophilus (GenBank® Accession

Without Wishing to be bound by theory, it is believed that
certain amino acids are useful for enhancing functionality of

No. YPi004303).
In some embodiments of the presently-disclosed subject
matter, the isolated polypeptide molecule is a fragment of
WtGBP that selectively binds glucose. For example, in some

55

embodiments, the polypeptide molecule comprises a frag
ment of WtGBP from E. coli including amino acids 14-296,
set forth in SEQ ID NO: 2 (referred to herein as tGBPl). For
another example, in some embodiments, the polypeptide
molecule comprises a fragment of WtGBP from E. coli
including amino acids 14-256, set forth in SEQ ID NO: 3
(referred to herein as tGBP2). For yet another example, in
some embodiments, the polypeptide molecule comprises a
fragment of WtGBP from E. coli including amino acids
14-226, set forth in SEQ ID NO: 4 (referred to herein as
tGBP3). For another example, in some embodiments, the

11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,

60

fragments of WtBGP provided from particular species. For
example, amino acids 14,91, 152, 158, 211, 236, and 256 of
WtGBP from E. coli (SEQ ID NO: 1) are believed to be
involved in the binding of glucose. As such, in some embodi
ments, the isolated polypeptide molecule is a fragment of
WtGBP from E. coli (SEQ ID NO: 1) that includes amino

acids 14, 91, 152, 158, 211, 236, and 256. In some embodi
ments, the isolated polypeptide molecule is a fragment of
WtGBP from E. coli (SEQ ID NO: 1) that includes at least 1,
2, 3, 4, 5, or 6 of the amino acids selected from amino acids
65

14, 91, 152, 158, 211, 236, and 256. Similarly, amino acid 13
ofWtGBP from T marilima (SEQ ID NO: 5) is believed to be
involved in the binding of glucose. As such, in some embodi

US 8,465,981 B2
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ments, the isolated polypeptide molecule is a fragment of
WtGBP from T marilima (SEQ ID NO: 5) that includes amino
acid 13.

In some embodiments of the presently-disclosed subject

polypeptide molecule comprises the sequence of WtGBP,
Wherein one or more natural amino acids are replaced With
one or more unnatural amino acids set forth in Table A. In
some embodiments, the WtGBP can be from E. coli. In some

matter, the isolated polypeptide molecule is an unnatural 5 embodiments, the WtGBP can be from T marilima. In some

analogue of WtGBP. For example, in some embodiments, the

embodiments, the WtGBP can be from T lhermophilus.
TABLE A
Structure of

Natural Amino Acid

Unnatural Amino Acid

Alanine

2-Pyridylalanine

Alanine

3-Pyridylalanine

Unnatural Amino Acid

—

N\ /
HZN
OH
O

Alanine

4-Pyridylalanine

Alanine

p-Iodophenylalanine

I

HZN
OH
O

Alanine

p-Brornophenylalanine

Br

HZN
OH

US 8,465 ,981 B2
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TABLE A-continued

Natural Arnino Acid

Unnatural Arnino Acid

Alanine

L-2-Arninobutyric acid

Sttucture of
Unnatural AIHlHO Acid

H

NH;

“I”

H3C

on
O

Glycine

L-Allylglycine

/
O

HZN
OH

Glycine

L-Propargylglycine

%
O

HZN

Glycine

2-Methoxy-phenylglycine

0/
OH

HZN
O

Glycine

3-Thienylglycine

/

S

OH

HZN
O

Leucine

5,5,5-trifluoro-DL-leucine

C133

0%}

OI

Lysine

D-Lysine

HZN

H O

H2NCH2(CH2)2CH2C:— C — OH

Phenylalanine

Alpha-methyl-L
phenylalanine

HN
2

0

HO

Phenylalanine

p-Arnino-DL-phenylalanine

NH;

O

US 8,465,981 B2
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TABLE A-continued

Natural Amino Acid

Unnatural Amino Acid

Structure of
Unnatural AIHIHO Acid

Tyrosine

3-Fluoro-L-tyrosine

O
OH

HZNhI“.
H

HO
Valine

F

D-Norvaline

In some embodiments, the polypeptide molecule com
prises the sequence of a fragment of WtGBP, wherein one or
more natural amino acids are replaced With one or more

unnatural amino acids set forth in Table A. In some embodi
ments, the WtGBP can be from E. coli. In some embodiments,
the WtGBP can be from T marilima. In some embodiments,
the WtGBP can be from T lhermophilus. In some embodi

(V) at least one proline is replaced With an unnatural pro
25

line;
(vi) at least one tyrosine is replaced With an unnatural

tyrosine;
(vii) at lest one valine is replaced With an unnatural valine;
(viii) at least one leucine is replaced With an unnatural
30

ments, the polypeptide molecule comprises the sequence of

leucine; and
(ix) at least one tryptophan is replaced With an unnatural

SEQ ID NO: 1, Wherein one or more natural amino acids are
replaced With one or more unnatural amino acids set forth in

tryptophan.

Table A. In some embodiments, the polypeptide molecule
comprises the sequence of SEQ ID NO: 2, Wherein one or

an unnatural alanine selected from: 2-Pyridylalanine, 3-Py

In some embodiment, at least one alanine is replaced With
35

unnatural amino acids set forth in Table A. In some embodi

In some embodiment, at least one glycine is replaced With

an unnatural glycine selected from: L-Allylglycine, L-Prop

ments, the polypeptide molecule comprises the sequence of
SEQ ID NO: 3, Wherein one or more natural amino acids are
replaced With one or more unnatural amino acids set forth in

argylglycine, 2-MethoXy-phenylglycine, and 3-Thienylgly
40

Table A. In some embodiments, the polypeptide molecule
comprises the sequence of SEQ ID NO: 4, Wherein one or

In some embodiments, at least one phenylalanine is

replaced With an unnatural phenylalanine selected from:

unnatural amino acids set forth in Table A. In some embodi
45

Alpha-methyl-L-phenylalanine, and p-Amino-DL-phenyla
lanine
In some embodiments, at least one proline is replaced With
an unnatural proline selected from: alpha-BenZyl-proline

SEQ ID NO: 5, Wherein one or more natural amino acids are
replaced With one or more unnatural amino acids set forth in

Table A. In some embodiments, the polypeptide molecule
comprises the sequence of SEQ ID NO: 6, Wherein one or

cine.
In some embodiments, at least one lysine is replaced With

D-lysine.

more natural amino acids are replaced With one or more

ments, the polypeptide molecule comprises the sequence of

ridylalanine, 4-Pyridylalanine, p-Iodophenylalanine, p-Bro
mophenylalanine, and L-2-Aminobutyric acid.

more natural amino acids are replaced With one or more

50

HCl, and gamma-(3-?uoro-benZyl)-L-proline-HCl.
In some embodiments, at least one tyrosine is replaced With

more natural amino acids are replaced With one or more

unnatural amino acids set forth in Table A. In some embodi

3-Fluoro-L-tyrosine.

ments, the polypeptide molecule comprises the sequence of

In some embodiments, at least one valine is replaced With
D-norvaline.
In some embodiments, at least one leucine is replaced With

SEQ ID NO: 7, Wherein one or more natural amino acids are
replaced With one or more unnatural amino acids set forth in

55

Table A.

5,5,5-tri?uoro-DL-leucine.

In some embodiments of the presently-disclosed subject
matter, the isolated polypeptide molecule is an unnatural
analogue of WtGBP, including one or more of the folloWing
substitutions:

In some embodiments, at least one tryptophan is replaced
With an unnatural tryptophan selected from: 5-HydroXy-L

tryptophan, 5-?uoro-L-tryptophan, 7-aZatryptophan, 6-aZa
60

(i) at least one alanine is replaced With an unnatural ala

In some embodiments, the polypeptide molecule is a

nine;

WtGBP or fragment thereof, Wherein one or more natural

(ii) at least one glycine is replaced With an unnatural gly

cine;
(iii) at least one lysine is replaced With an unnatural lysine;
(iv) at least one phenylalanine is replaced With an unnatural

phenylalanine;

tryptophan, and amino tryptophans.

65

leucines are replaced With unnatural leucines. Without Wish
ing to be bound by theory, it is believed that replacing one or
more natural leucines With unnatural leucines confers

enhanced thermal and chemical stability to the resulting
polypeptide analogue. In some embodiments, all natural leu

US 8,465,981 B2
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cines are replaced With unnatural leucines. In some embodi
ments, the unnatural leucines are 5,5,5-tri?uoro-DL-leucine.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 1, Wherein one or more
natural leucines are replaced With unnatural leucines. In some

tryptophans are replaced With unnatural tryptophans. Without
Wishing to be bound by theory, and With reference to the
description herein of biomarkers including an isolated
polypeptide molecule that is capable of emitting a signal
When binding glucose, it is believed that replacing one or
more natural tryptophans With unnatural tryptophans confers
an enhanced ability of the resulting biomarker to emit a sig
nal, e.g., ?uoresce. For example, as shoWn in FIG. 12, the
incorporation of 7-AZatryptophan in GRP enhances the inten
sity of ?uorescence emission. Further, as shoWn in FIG. 13
the incorporation of 7-AZatryptophan in GRP results in a

embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 1, Wherein one or more natural

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 1, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 2, Wherein one or more
natural leucines are replaced With unnatural leucines. In some

clearly distinguishable ?uorescence signature betWeen

embodiments, the polypeptide molecule comprises the

ral tryptophans are replaced With unnatural tryptophans. In

sequence of SEQ ID NO: 2, Wherein one or more natural

some embodiments, unnatural tryptophans are selected from:

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 2, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.

7-AZatryptophan GRP With and Without bound glucose
across different temperatures. In some embodiments all natu

5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan. In
some embodiments, the unnatural tryptophans are 5-?uorot

ryptophan.
20

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 3, Wherein one or more
natural leucines are replaced With an unnatural leucines. In

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises

some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 3, Wherein one or more natural

the sequence of SEQ ID NO: 1, Wherein one or more natural
25

In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 1, Wherein one or more natural

tryptophans are replaced With 5-?uorotryptophan. In some
30

sequence of SEQ ID NO: 1, Wherein all of the natural tryp
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 2, Wherein one or more

sequence of SEQ ID NO: 4, Wherein one or more natural

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 5, Wherein one or more
natural leucines are replaced With an unnatural leucines. In

embodiments, the polypeptide molecule comprises the

tophans are replaced With S-?uorotryptophan.

some embodiments, the polypeptide molecule comprises the
leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 4, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.

tryptophans are replaced With unnatural tryptophan selected

from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan.

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 3, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 4, Wherein one or more
natural leucines are replaced With an unnatural leucines. In

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 1, Wherein one or more

35

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 2, Wherein one or more natural

tryptophans are replaced With unnatural tryptophan selected

from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan.
40

In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 2, Wherein one or more natural

some embodiments, the polypeptide molecule comprises the

tryptophans are replaced With 5-?uorotryptophan. In some

sequence of SEQ ID NO: 5, Wherein one or more natural

embodiments, the polypeptide molecule comprises the

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 5, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 6, Wherein one or more
natural leucines are replaced With unnatural leucines. In some

sequence of SEQ ID NO: 2, Wherein all of the natural tryp
45

tophans are replaced With 5-?uorotryptophan.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 3, Wherein one or more

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises
50

the sequence of SEQ ID NO: 3, Wherein one or more natural

embodiments, the polypeptide molecule comprises the

tryptophans are replaced With unnatural tryptophan selected

sequence of SEQ ID NO: 6, Wherein one or more natural

from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan.

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 6, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.

In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 3, Wherein one or more natural
55

embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 3, Wherein all of the natural tryp

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 7, Wherein one or more
natural leucines are replaced With unnatural leucines. In some

embodiments, the polypeptide molecule comprises the

tophans are replaced With 5-?uorotryptophan.
60

WtGBP or fragment thereof, Wherein one or more natural

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 4, Wherein one or more

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises

sequence of SEQ ID NO: 7, Wherein one or more natural

leucines are replaced With 5,5,5-tri?uoro-DL-leucine. In
some embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 7, Wherein all of the natural leucines
are replaced With 5,5,5-tri?uoro-DL-leucine.
In some embodiments, the polypeptide molecule is a

tryptophans are replaced With 5-?uorotryptophan. In some

the sequence of SEQ ID NO: 4, Wherein one or more natural

tryptophans are replaced With unnatural tryptophan selected
65

from: S-hydroXy-L-tryptophan, and 5-?uoro-L-tryptophan.
In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 4, Wherein one or more natural

US 8,465,981 B2
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tryptophans are replaced With 5-?uorotryptophan. In some

described above With reference to unnatural analogues of
WtGBP. In some embodiments, the polypeptide molecule
comprises a fragment of WtGBP, Wherein at least one natural
amino acid is replaced With an unnatural amino acid, such as

embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 4, Wherein all of the natural tryp

tophans are replaced With 5-?uorotryptophan.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 5, Wherein one or more

an unnatural amino acid set forth in Table A. For another

example, in some embodiments, the polypeptide molecule
comprises a fragment of SEQ ID NOs: 2, 3, 4, 5, 6, or 7,

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises

Wherein at least one natural amino acid is replaced With an
unnatural amino acid, such as an unnatural amino acid set

the sequence of SEQ ID NO: 5, Wherein one or more natural

tryptophans are replaced With unnatural tryptophan selected

forth in TableA. For another example, in some embodiments,
the polypeptide molecule comprises a fragment of WtGBP

from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan.
In some embodiments, the polypeptide molecule comprises

Wherein at least one leucine is replaced With 5,5,5-tri?uoro
DL-leucine, and/or at least one tryptophan is replaced With

the sequence of SEQ ID NO: 5, Wherein one or more natural

tryptophans are replaced With 5-?uorotryptophan. In some

5-?uoro-L-tryptophan. In some embodiments, the polypep

embodiments, the polypeptide molecule comprises the

tide molecule comprises a fragment of WtGBP Wherein all
natural leucines are replaced With 5,5,5-tri?uoro-DL-leucine,
and/or all natural tryptophans are replaced With 5-?uoro-L

sequence of SEQ ID NO: 5, Wherein all of the natural tryp

tophans are replaced With 5-?uorotryptophan.
In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 6, Wherein one or more

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises

tryptophan.
20

the sequence of SEQ ID NO: 6, Wherein one or more natural

tryptophans are replaced With unnatural tryptophan selected

from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan.
In some embodiments, the polypeptide molecule comprises

25

the sequence of SEQ ID NO: 6, Wherein one or more natural

of the isolated polypeptide molecule. For another example, in

tryptophans are replaced With 5-?uorotryptophan. In some

some embodiments, Arg-Ser-His-His-His-His-His-His can

embodiments, the polypeptide molecule comprises the
sequence of SEQ ID NO: 6, Wherein all of the natural tryp

tophans are replaced With 5-?uorotryptophan.

30

In some embodiments, the polypeptide molecule com
prises the sequence of SEQ ID NO: 7, Wherein one or more

sor capable of detecting glucose. As used herein, the term

35

tryptophans are replaced With unnatural tryptophan selected

from: 5-hydroxy-L-tryptophan, and 5-?uoro-L-tryptophan.

ecule that is capable of selectively binding glucose, and a
label capable of generating a signal When the isolated
polypeptide molecule binds glucose. The isolated polypep
tide molecule of the biosensor can be an isolated polypeptide
molecule as described above. The label canbe associated With

In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 7, Wherein one or more natural

tryptophans are replaced With 5-?uorotryptophan. In some

be added to the C-terminus of the isolated polypeptide mol
ecule.
The presently-disclosed subject matter includes a biosen

“detect” means to determine quantitatively and/or qualita
tively. The biosensor includes an isolated polypeptide mol

natural tryptophans are replaced With unnatural tryptophans.
In some embodiments, the polypeptide molecule comprises
the sequence of SEQ ID NO: 7, Wherein one or more natural

In some embodiments, the isolated polypeptide molecule
is a fragment, unnatural analogue of WtGBP, or an unnatural
analogue fragment of WtGBP, Wherein one or more amino
acids have been added to the N-terminus and/or the C-termi
nus of the isolated polypeptide molecule. For example, in
some embodiments, Met-Arg can be added to the N-terminus

40

embodiments, the polypeptide molecule comprises the

a binding site of the isolated polypeptide molecule, Which
label is capable of generating a signal. For example, the label

sequence of SEQ ID NO: 7, Wherein all of the natural tryp

can be a ?uorescent label, e.g., ?uorophore, or an electro

tophans are replaced With 5-?uorotryptophan.

chemical label.
As used herein, the terms “label” and “labeled” refer to the

In some embodiments, the polypeptide molecule com
prises a WtGBP or fragment thereof, Wherein at least one

natural leucine is replaced With 5,5,5-tri?uoro-DL-leucine,

attachment of a moiety, capable of detection by spectro
scopic, radiologic, or other methods, to a probe molecule.

and at least one natural tryptophan is replaced With an unnatu

Thus, the terms “label” or “labeled” refer to incorporation or

45

ral tryptophan selected from 5-hydroxy-L-tryptophan, and

attachment, optionally covalently or non-covalently, of a

5-?uoro-L-tryptophan. In some embodiments, at least one

detectable marker into a molecule, such as a polypeptide.

natural leucine is replaced With 5,5,5-tri?uoro-DL-leucine,

50

and at least one natural tryptophan is replaced With 5-?uoro
L-tryptophan. In some embodiments, all natural leucines are

replaced With 5 ,5 ,5 -tri?uoro -DL-leucine, and all natural tryp
tophans are replaced With 5-?uoro-L-tryptophan.

Various methods of labeling polypeptides are knoWn in the art
and can be used. Speci?c examples are described herein.
Fluorescent probes that can be utiliZed include, but are not
limited to ?uorescein isothiocyanate; ?uorescein dichlorotri

aZine and ?uorinated analogs of ?uorescein; naphtho?uores

In some embodiments, When more than one of a particular 55 cein carboxylic acid and its succinimidyl ester; carbox

60

yrhodamine 6G; pyridyloxaZole derivatives; Cy2, 3, 3.5, 5,
5.5, and 7; phycoerythrin; phycoerythrin-Cy conjugates;
?uorescent species of succinimidyl esters, carboxylic acids,
isothiocyanates, sulfonyl chlorides, and dansyl chlorides,
including propionic acid succinimidyl esters, and pentanoic
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acid succinimidyl esters; succinimidyl esters of carboxytet
ramethylrhodamine; rhodamine Red-X succinimidyl ester;
Texas Red sulfonyl chloride; Texas Red-X succinimidyl
ester; Texas Red-X sodium tetra?uorophenol ester; Red-X;
Texas Red dyes; tetramethylrhodamine; lissamine rhodamine

natural amino acid is replaced With an unnatural amino acid,
different unnatural amino acids can be used. For one example,
in some embodiments, an unnatural analogue can include a

?rst natural tryptophan replaced With 5-hydroxy-L-tryp
tophan, and a second natural tryptophan replaced With

5-?uoro-L-tryptophan.
In some embodiments of the presently-disclosed subject
matter, the isolated polypeptide molecule is an unnatural

analogue fragment of WtGBP that selectively binds glucose.
In embodiments Where the polypeptide molecule comprises
an unnatural analogue fragment of WtGBP, natural amino
acids can be replaced With unnatural amino acids, as

B; tetramethylrhodamine; tetramethylrhodamine isothiocy
anate; naphtho?uoresceins; coumarin derivatives (e. g.,

US 8,465,981 B2
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hydroxycoumarin, aminocoumarin, and methoxycoumarin);
pyrenes; pyridyloxazole derivatives; dapoxyl dyes; Cascade

For example, the biosensors disclosed herein comprising
novel glucose recognition peptides can be employed for the
development of sensing systems on non-catheter platform

Blue and Yellow dyes; benzofuran isothiocyanates; sodium

tetra?uorophenols;

4,4-di?uoro-4-bora-3a,4a-diaza-s-in

systems. For example, the biosensors disclosed herein can be
used to quantitate glucose levels on both microtiter plate and
miniaturized micro?uidics platforms, Which are popular in

dacene; ALEXA FLUORS® (e.g., 350, 430,488, 532, 546,
555, 568, 594, 633, 647, 660, 680, 700, and 750); green
?uorescent protein; yelloW ?uorescent protein; and fruit ?uo

high-throughput screening, clinical laboratory practice, and
in the development of point-of-care diagnostic equipment.

rescent proteins. The peak excitation and emission Wave
lengths Will vary for these compounds and selection of a
particular ?uorescent probe for a particular application can be

Additionally, presently-disclosed biosensors can be immobi

made in part based on excitation and/or emission Wave

color change Would correlate to glucose levels. These paper

lengths.

strips Would be a practical and competitive option for patient
self-monitoring of glucose levels. Moreover, the dynamic
range of the glucose recognition peptides of the presently
disclosed subject matter can permit salivary analysis of glu

lized on affordable and robust paper strips, Whose visible

In some embodiments, the isolated polypeptide molecule
is a fragment, an unnatural analogue, or an unnatural ana

logue fragment of a WtGBP; and the label is attached to an
amino acid residue of the isolated polypeptide molecule. The

cose levels, instead of the painful and invasive ?nger prick

label can be attached to one of the folloWing amino acid sites

close to the binding site of the isolated polypeptide molecule,

20

disclosed herein and contained Within hydrogel, as disclosed
for example in the Daunert et al. Application can also be used

and identi?ed With reference to WtGBP of SEQ ID NO: 1 : Asp

13,Asp 44, Val 68, Ala 71, Phe 90, Lys 92, Glu 93, Pro 94, Lys
97, Gly 109, Thr 110, Asp 111, Gly 151, Pro 153, Ala 155,
Asp 184, Asp 212, Leu 255, Ala 258, Asn 260, Ala 262, Arg
292, Val 293, and Pro 294. The label can be a ?uorophore,
such as a ?uorophore selected from: BODIPY 630/650 (Bro

for the development and improvement implantable drug
delivery devices and contact lens glucose sensors. As an
25

30

tion peptide-hydrogel derived device. Additionally, current
contact lens glucose sensors have a sensing plastic chip incor

The biosensors of the presently-disclosed subject matter
can be utilized in a number of different capacities in order to
35

glucose levels in tears, thus alerting the patient if insulin is
40

needed. One advantage the biosensors described herein have
over this current contact lens scheme is that the glucose
sensor disclosed herein can be hydrogel based. Hydrogels are

more Water and oxygen permeable than the plastic chips that

are currently used, and this permeability is quite important for
45

both the comfort and long term optical health of the contact
lens Wearer.

on Aug. 6, 2008 (hereinafter referred to as the “Daunert et al.

The presently-disclosed subj ect matter is further illustrated

Application), Which is incorporated herein by reference in its

by the folloWing speci?c but non-limiting examples. The

entirety.
In addition to coupling With catheter systems, the biosen
sors disclosed herein can also be utilized in several other

porated into the regular corrective lens. This plastic chip
changes colors via holographic sensing methods and boron
containing ?uorophores. These color changes are visible to
the Wearer, With different colors corresponding to different

entitled “DEVICE FOR DETECTION OF MOLECULES

OF INTEREST,” claiming priority from US. Provisional
Application Ser. Nos. 60/954,269 and 60/954,348, and ?led

of a reversible insulin-containing drug reservoir. In this man
ner glucose levels can be both monitored and corrected in

diabetic patients With a glucose responsive glucose recogni

boxamide).
detect glucose, both in vitro and in vivo. As one non-limiting
example, the biosensor can be coupled With a catheter for
continuous in vivo detection of glucose in a body of a subject.
Any knoWn catheter suitable for implantation in a body canbe
utilized With the biosensors disclosed herein, including but
not limited to catheter systems disclosed in International
Patent Application No. PCT/US08/732338 to Daunert et al.

example of a potential use in implantable drug delivery
devices, the change in ?uorescent or electrical signal caused

by glucose binding to the appropriately labeled glucose rec
ognition peptides can be translated to the opening and closing

momethyl); ALEXA FLUORS® 680 679/702 (Maleimide);

NBD 478/541 (Haloacetamide); PyMPO 415/570 (Haloac
etamide); Texas Red 595/615 (Maleimide); and MDCC (N
[2-(1 -maleimidyl(ethyl] -7-(diethylamino)coumarin-3 -car

method commonly used today.
In addition, the non-natural glucose recognition peptides

50

systems for glucose detection. The incorporation of non
natural amino acids into single locations Within glucose rec

folloWing examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the

presently-disclosed subject matter.

ognition peptides can alloW for site-speci?c labeling With
?uorophores, electrochemical tags, etc., due to the enhanced
functional diversity that non-natural amino acids have in
comparison to their canonical counterparts. This site speci?c

potential provides for greater control and analytical reproduc
ibility When developing glucose biosensors With non-natural
glucose recognition peptides. The incorporation of non-natu
ral amino acids further permits for the site-speci?c immobi
lization of these glucose recognition peptides, Which can
decrease the activity loss that is commonly encountered upon
peptide immobilization. The retention of this glucose respon
sive activity can be useful in optimizing both hydrogel-cath

55

EXAMPLES

Expression and Labeling of Isolated Polypeptide Mol
ecules. In order to obtain the gene for insertion into an expres
sion vector, PCR ampli?cation Was employed. Primers Were
60

designed to amplify isolated polypeptide molecules of inter

eter based glucose sensors disclosed in the Daunert et al.

est, e.g., polypeptide molecules of SEQ ID NOS: 1-7, and a
fragment including amino acids 87-271 of SEQ ID NO: 1.
Table B shoWs data from the fragment containing amino acids
87-271 from E. coli. This fragment shoWed large error and no
clear trend in response to glucose, Which demonstrates that
rational design of truncated forms of WtGBPs is necessary to

Application and in developing alternative sensor designs.

render a responsive glucose recognition peptide.
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TABLE B

TABLE c
Fluorescence signal quenching in response to varying

Glucose

Fluorescence

Concentration

Intensity

Standard

(M)

(AVG)

Deviation

concentration of glucose obtained from tGBPs.

Percent Fluorescence Quenching

0

485.282

17.004

Glucose, M

tGBPl

tGBP2

1.00E-08

442.682

32.888

1x 10’6

—0.09539

1.748188

1.00E-07

463.041

20.018

1.00E-06

497.146

22.400

1.00E-05

478.877

36.678

1.00E-04

467.383

41.020

1
1
1
1
1

2.907571
2.432862
7.5538
14.60875
20.36978

2.794934
5.87441
8.966095
7.50211
6.265703

1.00E-03

468.792

23.450

x
x
x
x
x

10’5
1041
10’3
10’2
10’1

Unnatural Analogues of WtGBP With Unnatural Tryp
Once the PCR ampli?ed gene fragments Were obtained,
they Were inserted into expression vector pQE70. The con
structed expression plasmids Were then transformed into the
auxotrophic strain of E. coli. Protein expression Was per

formed using medium shift method. A single freshly trans

tophans. Unnatural analogues of WtGBP from E. coli Were

20

formed colony Was used to inoculate 5 mL of M9 media

supplemented With 0.4% glucose; 1 mM MgSO4; 0.1 mM
CaCl2; 1 mM Thiamine; 0.1 volume of a solution containing
0.01% (W/v) each of 20 amino acids, less any amino acid that
is to be replaced by unnatural amino acids (e.g., each of 19
amino acids Where one is to be replaced); 40 ug/mL of the

25

priate amount of antibiotic. T his culture Was alloWed to groW
30

same ingredients Was inoculated With the overnight groWn 5
mL culture. This culture Was then groWn until the optical
density (OD6OO) Was about 0.5. The cells Were then centri
fuged at 10000 rpm for 10 min, 250 C., the supernatant Was
discarded and the cells Were resuspended in a 0.9% NaCl

solution for Washing, and this Was repeated three times. The
cells Were then resuspended in 500 mL M9 minimal media
Which Was supplemented With 0.4% glucose, 1 mM MgSO4,
0.1 mM CaCl2, 1 mM Thiamine, 0.1 volume of a solution
containing 0.01% (W/v) each of 20 amino acids less any

35

40

This culture Was alloWed to groW overnight at 37° C., 250
rpm. 500 mL culture containing the same ingredients Was
inoculated With the overnight groWn 5 mL culture. This cul
ture Was then groWn till the optical density (OD6OO) Was about
0.5. The cells Were then centrifuged at 10000 rpm for 10 min,
250 C., the supernatant Was discarded and the cells Were
resuspended in a 0.9% NaCl solution for Washing, and this
Was repeated three times. The cells Were then resuspended in
500 mL M9 minimal media Which Was supplemented With

of 18 amino acids (less Trp and Leu), 40 ug/mL Leu, 100

ug/mL Ampicillin and 35 ug/mL Chloramphenicol, and
45

culture and Was groWn overnight at 37° C. The cells Were

harvested by centrifugation and the protein Was puri?edusing
Ni-NTA resin since GBP mutant has His-tag. The puri?ed
protein Was then labeled With ?uorophore MDCC (N-[2-(1

ug/mL Leu, 40 ug/mL Trp, 100 ug/mL Ampicillin, and 35

ug/mL Chloramphenicol.

0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 1 mM Thia
mine, 0.1 volume of a solution containing 0.01% (W/v) each

amino acid(s) to be replaced by unnatural amino acids (e.g.,
19 amino acids), appropriate amount of antibiotic, and groWn
at 37° C. for 30 min to further deplete natural amino acid that
has to be replaced by the unnatural amino acid. 1 mM IPTG
Was then added With 0.1 mM of unnatural amino acid to the

formed colony Was used to inoculate 5 mL of M9 media

supplemented With 0.4% glucose, 1 mM MgSO4, 0.1 mM
CaCl2, 1 mM Thiamine, 0.1 volume of a solution containing
0.01% (W/v) each of 18 amino acids (less Trp and Leu), 40

remaining amino acid(s) (e.g., 20”’ amino acid), and appro
overnight at 37° C., 250 rpm. 500 mL culture containing the

produced, Where natural tryptophans Were replaced With
unnatural tryptophans. Tryptophan auxotrophic strain of E.
coli (#27873) Was obtained. Plasmid placI and plasmid
pQE70 containing the genetic sequence of the WtGBP
mutated at 152 (containing a cysteine in this position for
?uorophore attachment) Were transformed into the tryp
tophan auxotrophic strain of E. coli. Protein expression Was
performed using medium shift method. A single freshly trans

50

groWn at 37° C. for 30 min to further deplete natural tryp
tophan. 1 mM IPTG Was then added With 0.1 mM 5-Fluorot
ryptophan to the culture and Was groWn overnight at 37° C.

The cells Were harvested by centrifugation and the protein
Was puri?ed using Ni-NTA resin since the produced mutant
has a His-tag. The puri?ed protein Was then labeled With

maleimidyl(ethyl]—7-(diethylamino)coumarin-3-carboxam

?uorophore MDCC (N-[2-(1-maleimidyl)ethyl]—7-(diethy

ide), e.g., labeled at cysteine-152 of SEQ ID NO: 1.
Fragments of WtGBP in Response to Glucose. In order to

lamino)coumarin-3-carboxamide).

check for activity of the labeled tGBPs, an assay Was per

formed. Upon glucose binding, the proteins should undergo a

55

conformational change, resulting in a change in the local

groWing the glucose recognition protein With unnatural leu

environment of the ?uorophore molecule, Which leads to a
change in the ?uorescence signal observed. The assay Was

carried out by preparing glucose solutions of concentrations
ranging from 1><10_lM to 1><10_6M. These glucose standards

cines. The procedure for groWing and harvesting the cells Was
similar to the procedure described above With reference to
60

Unnatural Analogues of WtGBP in Response to Glucose.
Labeled protein Was diluted to 5x10‘7 M and 180 pL of this
diluted labeled protein Was incubated With 20 pL of different

concentration of 1><10_7M. The resulting ?uorescence inten
sity Was measured. The results obtained from one study

C.

unnatural analogues With unnatural tryptophans, except that
no Chloramphenicol Was added to the cultures.

Were then added to 180 pL samples of the labeled tGBPs at a

including the isolated polypeptide molecules of SEQ ID NO:
2 (tGBPl) and SEQ ID NO: 3 (tGBP2) are presented in Table

Unnatural Analogues of WtGBP With Unnatural Leucines.
Unnatural analogues of WtGBP from E. coli Were produced,
Where natural leucines Were replaced With unnatural leucines.
Leucine auxotrophic strain of E. coli HB101F Was used for

65

concentrations of glucose (10'2 M-10'8 M) for 15 min at
room temperature. Fluorescence of the samples Was then

measured using a Carry Eclipse Fluorimeter.

US 8,465,981 B2
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logue of WtGBP including unnatural tryptophan, immobi

FIG. 3 is a dose response curve for glucose With an unnatu

lized on a ?ber optic tip. A dose-dependent change in ?uo

ral analogue of a WtGBP including unnatural tryptophan. The
unnatural analogue of WtGBP is the isolated polypeptide of
SEQ ID NO: 1, Where all natural tryptophans are replaced

rescence intensities observed When the unnatural analogue

fragment is contacted With increasing concentrations of glu
cose.

With 5-?uorotryptophans. A dose-dependent change in ?uo

Circular dichroism (CD) spectra Were obtained to deter

rescence intensities observed When the unnatural analogue is

mine the structural integrity at different temperatures, i.e.,
thermal stability, of an unnatural analogue fragment of a

contacted With increasing concentrations of glucose.
FIG. 4 is a dose response curve for glucose With an unnatu

WtGBP including unnatural leucines, as compared to a

ral analogue fragment of a WtGBP including unnatural tryp
tophan. The unnatural analogue fragment of WtGBP is the
isolated polypeptide of SEQ ID NO: 2, Where all natural
tryptophans are replaced With 5-?uorotryptophans. A dose
dependent change in ?uorescence intensities observed When
the unnatural analogue fragment is contacted With increasing
concentrations of glucose.

WtGBP. FIG. 10 is a circular dichroism spectrum of an

unnatural analogue fragment of a WtGBP. The unnatural ana

logue of WtGBP is the isolated polypeptide of SEQ ID NO: 2,
Where all natural leucines are replaced With 5,5,5-tri?uoro
leucines. FIG. 11 is a CD spectrum of a WtGBP, including the
isolated polypeptide of SEQ ID NO: 1. The CD spectrum of
FIG. 11 shoWs that the WtGBP is stable Within the tempera
ture range of about 350 C. to about 55° C. The CD spectrum

FIG. 5 is a dose response curve for glucose With an unnatu

ral analogue fragment of a WtGBP including unnatural tryp
tophan. The unnatural analogue fragment of WtGBP is the
isolated polypeptide of SEQ ID NO: 3, Where all natural
tryptophans are replaced With 5-?uorotryptophans. A dose
dependent change in ?uorescence intensities observed When
the unnatural analogue fragment is contacted With increasing
concentrations of glucose.
FIG. 6 is a dose response curve for glucose With an unnatu

ral analogue of a WtGBP including unnatural leucine. The
unnatural analogue of WtGBP is the isolated polypeptide of
SEQ ID NO: 1, Where all natural leucines are replaced With

of FIG. 10 shoWs that the unnatural analogue including
unnatural leucines has better thermal stability, shoWing sta
20

contacted With increasing concentrations of glucose.

ecule of interest includes initially immersing a tip of an opti
25

30

ral analogue fragment of a WtGBP including unnatural leu
cine. The unnatural analogue fragment of WtGBP is the iso
lated polypeptide of SEQ ID NO: 2, Where all natural leucines
are replaced With 5,5,5-tri?uoroleucines. A dose-dependent
change in ?uorescence intensities observed When the unnatu
ral analogue fragment is contacted With increasing concen
trations of glucose.
FIG. 8 is a dose response curve for glucose With an unnatu

the unnatural analogue fragment is contacted With increasing
concentrations of glucose.
Labeled protein Was immobilized in an acrylamide based
hydrogel and the hydrogel Was then immobilized on the tip of

cal ?ber having a biosensor positioned on said tip into a
sample. The biosensor includes an isolated peptide having a

binding site that selectively binds said molecule of interest.
Upon binding the molecule of interest, the peptide emits a
signal that is transmitted by said optical ?ber, to thereby
detect said molecule of interest. The method further includes
collecting the signal With a detection and data collection

device operably connected With the optical ?ber and then
correlating the signal to an amount of the molecule of interest.
The amount of the molecule of interest can then be displayed.
In some embodiments, the molecule of interest can be glucose
or IL-6, and the biosensor peptide can be a glucose binding

FIG. 7 is a dose response curve for glucose With an unnatu

ral analogue fragment of a WtGBP including unnatural leu
cine. The unnatural analogue fragment of a WtGBP is the
isolated polypeptide of SEQ ID NO: 3, Where all natural
leucines are replaced With 5,5,5-tri?uoroleucines. A dose
dependent change in ?uorescence intensities observed When

Method of Detecting Molecules of Interest
An exemplary method for continuous detection of a mol

5,5,5-tri?uoroleucines. A dose-dependent change in ?uores
cence intensities observed When the unnatural analogue is

bility over a Wider range of about 350 C. to about 75° C.

protein or an IL-6-speci?c antibody, respectively.
In this exemplary embodiment, the peptide has high stabil
ity at physiological conditions and is incorporated Within an
optically transparent hydrogel positioned on said distal tip.
40

The biosensor includes a label associated With the binding
site. The label generates the signal and is selected from a
?uorescent label and an electrochemical label.

When the molecule of interest is glucose, the hydrogel can
include a precursor solution of bisacrylamide, acrylamide,
45

buffer solution, glycerol, glucose binding protein, acrylic
acid, and 2,2-Diethoxyacetaphenone. The precursor solution
can be UV polymerized for approximately 30 minutes to form

the hydrogel incorporated With the peptide.
Finally, the sample can be a blood stream or body ?uid in a
body of a subject, in vivo, or can be an in vitro sample.
It Will be understood that various details of the presently

an optical ?ber. The tip of the optical ?ber With immobilized
hydrogel Was then dipped in glucose solutions of different
concentration made in 10 mM HEPES, 0.2 mM CaCl2, pH 8.0
buffer and the change in ?uorescence intensity Was measured
using an Ocean Optics ?ber optic instrument. FIG. 9 is a dose

thermore, the foregoing description is for the purpose of

response curve for glucose in buffer With an unnatural ana

illustration only, and not for the purpose of limitation.

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 309
TYPE: PRT
ORGANISM: E.

<400> SEQUENCE:

l

Coli

disclosed subject matter can be changed Without departing
from the scope of the subject matter disclosed herein. Fur

